
Browsing restrictions can be lifted for a fee.
Maywufa Company Ltd. manufactures and sells hair and skin care products under the Maywufa brand in Taiwan. It offers hair care products; health care products and food supplements; and mother and baby skin care products under the mustela brand. The company also provides pharmaceuticals and medical devices, such as PG2 Lyophilized injection for treatment of cancer-related fatigue; AmCad-UT Detection device, an ultrasound CAD for thyroid cancer detection; Bio-Three tablets for the treatment of mild diarrhea, abdominal pain, and constipation; and Cerebrolysin, a supplementary nutrient boost for patients who cannot ingest adequate food and patients who have difficulties in the digestion, absorption, synthesis, and utilization of proteins, as well as for patients suffering from severe trauma, burns, fractures, insufficient protein intake, or malnutrition. In addition, it sells and distributes pharmaceutical products; and operates and manages pharmacy chain under the Pharmacy Franchise name. Maywufa Company Ltd. was founded in 1976 and is headquartered in Taipei, Taiwan.
1731
美吾華
-0.23%
(-0.00)
The most recent financial report for 美吾華 (1731) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 1731's short-term business performance and financial health. For the latest updates on 1731's earnings releases, visit this page regularly.
According to historical valuation range analysis, 美吾華 (1731)'s current price-to-earnings (P/E) ratio is 12.65, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 美吾華 (1731) reported an Operating Profit of 40.78M with an Operating Margin of 9.83% this period, representing a growth of 11.46% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 美吾華 (1731) announced revenue of 414.83M, with a Year-Over-Year growth rate of 10.3%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 美吾華 (1731) held Total Cash and Cash Equivalents of 225.06M, accounting for 0.07 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 美吾華 (1731) achieved the “three margins increasing” benchmark, with a gross margin of 62.5%%, operating margin of 9.83%%, and net margin of 8.52%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 1731's profit trajectory and future growth potential.
According to the past four quarterly reports, 美吾華 (1731)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.27. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
美吾華 (1731)'s Free Cash Flow (FCF) for the period is 1.26M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 100.94% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.